Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates.
BACKGROUND
Several strategies are being developed to reduce the risk of pathogen transmission associated with platelet (PLT) transfusion.


METHODS
The impact of a new technology for pathogen reduction based on riboflavin plus illumination (Mirasol PRT, Navigant Biotechnologies, Inc.) at 6.2 and 12.3 J per mL on functional and biochemical characteristics of PLTs was evaluated. PLT concentrates (PCs) obtained by apheresis were treated with Mirasol PRT and stored at 22 degrees C. Modifications in major PLT glycoproteins (GPIbalpha, GPIV, and GPIIb-IIIa), adhesive ligands (von Willebrand factor [VWF], fibrinogen [Fg], and fibronectin), activation antigens (P-selectin and LIMP), and apoptotic markers (annexin V binding and factor [F]Va) were analyzed by flow cytometry. Adhesive and cohesive PLT functions were evaluated with well-established perfusion models. Studies were performed on the preparation day (Day 0) and during PCs storage (Days 3 and 5).


RESULTS
Levels of glycoproteins remained stable during storage in PCs treated with 6.2 J per mL pathogen reduction technology (PRT) and similar to those observed in nontreated PCs. When 12.3 J per mL PRT was applied, however, levels of GPIbalpha moderately decreased on Days 3 and 5. VWF, Fg, and FVa were not modified in their expression levels, either by treatment or by storage period. Fibronectin appeared more elevated in all PRT samples. A progressive increase in P-selectin and LIMP expression and in annexin V binding was observed during storage of PRT-treated PCs. Functional studies indicated that 6.2 J per mL Mirasol PRT-treated PLTs preserved adhesive and cohesive functions to levels compatible with those observed in the respective control PCs.


CONCLUSIONS
PLT function was well preserved in PCs treated with 6.2 J per mL Mirasol PRT and stored for 5 days.
Perez-Pujol
S
S
Hemotherapy-Hemostasis Service, CDB, Hospital Clinic, IDIBAPS, University of Barcelona, Spain.
Tonda
R
R
Lozano
M
M
Fuste
B
B
Lopez-Vilchez
I
I
Galan
A M
AM
Li
J
J
Goodrich
R
R
Escolar
G
G
D017304:Annexin A5 / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D015703:Antigens, CD / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D001792:Blood Platelets / Q000737:chemistry / Q000166:cytology / Q000187:drug effects* / Q000502:physiology / Q000528:radiation effects*; D001793:Blood Preservation; D005340:Fibrinogen / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D005353:Fibronectins / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D005434:Flow Cytometry; D006801:Humans; D051907:Lysosomal Membrane Proteins; D019007:P-Selectin / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D015539:Platelet Activation / Q000187:drug effects / Q000528:radiation effects; D010973:Platelet Adhesiveness / Q000187:drug effects / Q000528:radiation effects; D010976:Platelet Count; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D019038:Platelet Glycoprotein GPIb-IX Complex / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D040201:Platelet Membrane Glycoprotein IIb / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects; D017713:Platelet Transfusion; D010983:Plateletpheresis; D012256:Riboflavin / Q000494:pharmacology*; D013696:Temperature; D013997:Time Factors; D014466:Ultraviolet Rays; D014841:von Willebrand Factor / Q000032:analysis / Q000187:drug effects / Q000528:radiation effects
D017304:Annexin A5; D015703:Antigens, CD; D005353:Fibronectins; D051907:Lysosomal Membrane Proteins; D019007:P-Selectin; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D019038:Platelet Glycoprotein GPIb-IX Complex; D040201:Platelet Membrane Glycoprotein IIb; D014841:von Willebrand Factor; D005340:Fibrinogen; D012256:Riboflavin